KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Other financing activities (2016 - 2025)

Quest Diagnostics' Other financing activities history spans 17 years, with the latest figure at $100.0 million for Q4 2025.

  • For Q4 2025, Other financing activities rose 75.44% year-over-year to $100.0 million; the TTM value through Dec 2025 reached $39.0 million, up 85.71%, while the annual FY2025 figure was $39.0 million, 85.71% up from the prior year.
  • Other financing activities for Q4 2025 was $100.0 million at Quest Diagnostics, up from -$11.0 million in the prior quarter.
  • Across five years, Other financing activities topped out at $100.0 million in Q4 2025 and bottomed at -$61.0 million in Q1 2025.
  • The 5-year median for Other financing activities is $3.0 million (2024), against an average of -$157894.7.
  • The largest annual shift saw Other financing activities tumbled 1075.0% in 2021 before it skyrocketed 244.44% in 2023.
  • A 5-year view of Other financing activities shows it stood at $21.0 million in 2021, then crashed by 195.24% to -$20.0 million in 2022, then skyrocketed by 190.0% to $18.0 million in 2023, then surged by 216.67% to $57.0 million in 2024, then surged by 75.44% to $100.0 million in 2025.
  • Per Business Quant, the three most recent readings for DGX's Other financing activities are $100.0 million (Q4 2025), -$11.0 million (Q3 2025), and $11.0 million (Q2 2025).